Three potential coronavirus vaccines are making fast progress in early-stage testing in volunteers in China and the U.S., but it’s still a long road to prove if they’ll really work against COVID-19.

CanSino Biologics of China has begun the second phase of testing its vaccine candidate, the Chinese Ministry of Science and Technology said Tuesday.

In the U.S., a shot made by the National Institutes of Health and Moderna Inc. isn’t far behind. The first person to receive that experimental vaccine last month returned to a Seattle clinic Tuesday for a second dose.

NIH infectious disease chief Dr. Anthony Fauci said there are “no red flags” so far and he hoped the next, larger phase of testing could begin around June.


A third candidate, from Inovio Pharmaceuticals, began giving experimental shots for first-step safety testing last week in the U.S. and hopes to expand its studies to China.

Newsletter Get our free Coronavirus Today newsletter Sign up for the latest news, best stories and what they mean for you, plus answers to your questions. Enter Email Address Sign Me Up You may occasionally receive promotional content from the Los Angeles Times.

Initial tests in a clinical trial focus on safety, and researchers in both countries are trying out different doses of different types of shots.

But moving into the second phase is a critical step that allows vaccines to be tested in many more people to look for signs that they protect against infection.


Last week, CanSino filed a report showing it aimed to enroll 500 people in its phase 2 study, comparing two doses of the vaccine to placebo shots. As of Monday, 273 of the volunteers had been injected, state media said.

Looking ahead, Fauci said if the new coronavirus continues to circulate widely enough over the summer and fall, it might be possible to finish larger studies slightly sooner than the 12 to 18 months he’d originally predicted — maybe toward “mid to late winter of next season.”

“Please let me say this caveat: That is assuming that it’s effective. See, that’s the big ‘if,’” Fauci stressed. “It’s got to be effective and it’s got to be safe.”


During a news conference in China, authorities also cautioned that the studies must be done properly.

“Although we are in an emergency, we cannot lower the standards of safety and effectiveness in the reviews of vaccines,” said Wang Junzhi, a Chinese biopharmaceutical expert. “The public is paying huge attention.”

The World Health Organization this week counted more than five dozen other vaccine candidates in earlier stages of development being pursued around the world. Many research groups are teaming up to speed the work. On Tuesday, vaccine giants Sanofi and GSK announced that they had became the latest to partner on a candidate.

The WHO’s list includes a wide variety of ways to make vaccines, so if one approach doesn’t pan out, perhaps another one will.


CanSino’s vaccine is based on a genetically engineered shot it created to guard against Ebola. The leading U.S. candidates use a different approach, made from copies of a piece of the coronavirus’ genetic code.